Tara Masterson

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 241 citations · Full text

Medicine, Oncology, Pharmacology +14

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Saad Z. Usmani, Hareth Nahi, María‐Victoria Mateos et al. · Blood · 2019 · 118 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).

Carolina Schinke, Cyrille Touzeau, Monique C. Minnema et al. · Journal of Clinical Oncology · 2023 · 89 citations

Medicine, Pharmacology, Pharmacotherapy +16

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

Ajai Chari, Cyrille Touzeau, Carolina Schinke et al. · The Lancet Haematology · 2025 · 83 citations · Full text

Medicine, Oncology, Pharmacology +12

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy

Mark C. Genovese, Elizabeth C. Hsia, Stanley M. Belkowski et al. · The Journal of Rheumatology · 2015 · 68 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16